BioNTech says 90% of 2024 revenues will accrue at end of year

FRANKFURT, May 6 (Reuters) - Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year.

BioNTech said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros.

"BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added. ($1 = 0.9287 euros) (Reporting by Ludwig Burger, Editing by Rachel More)